ARCHIVES

Aflibercept-Docetaxel Combination Misses Primary Survival Endpoint

This article is from The Cancer Letter archive.

Vol. 34 No. 3 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

NCI Launches ALCHEMIST

September 5, 2014

Diet/Cancer Product ad Seminar Consensus: It’s Okay When Limited To Categories Of Food

November 7, 1986

IM Recommends Pay Increase for Many At NIH, Other Steps; Adamson Objects To “Primrose Path Of Centralization

March 3, 1989

NCI CTEP-Approved Trials For the Month of March

March 28, 2014

Taxol Plus Carboplatin Increased Survival Of NSCLC In Patients 70 And Older

June 25, 2010

CPRIT Sets Funding Priorities For Rare and Pediatric Cancers

November 14, 2014